Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)

University of Pittsburgh

Status: Withdrawn

Conditions: Clostridium Difficile Infection (CDI)

Treatments: Drug: Fidaxomicin

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04070352

PRO18110022

Details and patient eligibility

About

This is a single center collection of discarded biological samples and electronic medical review (EMR) data on patients who are hospitalized with clostridium difficile infections and treated with Fidaxomicin

Full description

This single site study will be a clinical research data base of patients hospitalized and diagnosed with Clostridium difficile infection (CDI), treated with Fidaxomicin and willing to allow us to collect discard biological samples for testing and analysis in the investigators lab. An additional blood sample will be obtained if a clinically indicated bronchoscopy is performed as to measure the amount of medication in the BAL. We will also complete a medical record review will also occur.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. ≥18 years of age
2. Currently an inpatient at UPMC Presbyterian
3. Diagnosed with an CDI
4. Being treated with Fidaxomicin

Exclusion criteria

not meeting entry criteria

Trial design

0 participants in 1 patient group

clostridium difficile infection (CDI)

Description:

This is a pilot project. Data from electronic medical records will be collected on all patients diagnosed with clostridium difficile infection and who are receiving fidaxomicin as part of their treatment. A total of 50 patients will be enrolled

Treatment:

Drug: Fidaxomicin